These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25287679)

  • 1. Hepatobiliary agents and their role in LI-RADS.
    Hope TA; Fowler KJ; Sirlin CB; Costa EA; Yee J; Yeh BM; Heiken JP
    Abdom Imaging; 2015 Mar; 40(3):613-25. PubMed ID: 25287679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
    Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
    Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
    Allen BC; Ho LM; Jaffe TA; Miller CM; Mazurowski MA; Bashir MR
    AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS.
    Cha DI; Choi GS; Kim YK; Kim JM; Kang TW; Song KD; Ahn SH
    Eur Radiol; 2020 Jul; 30(7):3723-3734. PubMed ID: 32128620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
    Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
    Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
    Santillan C; Fowler K; Kono Y; Chernyak V
    Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in Liver Imaging Reporting and Data System Characterization of Focal Liver Lesions Using Gadoxetate Disodium Magnetic Resonance Imaging Compared With Contrast-Enhanced Computed Tomography.
    Hope TA; Aslam R; Weinstein S; Yeh BM; Corvera CU; Monto A; Yee J
    J Comput Assist Tomogr; 2017; 41(3):376-381. PubMed ID: 27801693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System.
    Min JH; Kim JM; Kim YK; Kang TW; Lee SJ; Choi GS; Choi SY; Ahn S
    Hepatology; 2018 Dec; 68(6):2254-2266. PubMed ID: 30070365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of hepatocellular carcinoma: new approaches to diagnosis.
    Anis M
    Clin Liver Dis; 2015 May; 19(2):325-40. PubMed ID: 25921666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features.
    Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM
    J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of gadoxetate disodium-enhanced MRI sequences for measuring hepatic observation size and its implication of LI-RADS classification.
    Choi JY; Ha J; Choi SH; Kang HJ; Kim SY; Kim KW
    Abdom Radiol (NY); 2022 Mar; 47(3):1024-1031. PubMed ID: 35020008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Liver Imaging and Reporting Data System Categorization Between MRI and CT.
    Corwin MT; Fananapazir G; Jin M; Lamba R; Bashir MR
    AJR Am J Roentgenol; 2016 Feb; 206(2):307-12. PubMed ID: 26797357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
    Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
    J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging features of hepatic inflammatory pseudotumor: distinction from colorectal liver metastasis using gadoxetate disodium-enhanced magnetic resonance imaging.
    Ichikawa S; Motosugi U; Suzuki T; Shimizu T; Onishi H
    Abdom Radiol (NY); 2020 Aug; 45(8):2400-2408. PubMed ID: 32468212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm.
    Becker AS; Barth BK; Marquez PH; Donati OF; Ulbrich EJ; Karlo C; Reiner CS; Fischer MA
    Eur J Radiol; 2017 Jan; 86():33-40. PubMed ID: 28027763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.
    Motosugi U; Bannas P; Sano K; Reeder SB
    J Magn Reson Imaging; 2015 Feb; 41(2):251-65. PubMed ID: 25104398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.